Description
The marker is associated with the peculiarities of drug metabolism in the liver. It is examined to identify the physiological efficacy of using drugs of the following groups: antiplatelet agents (clopidogrel and its analogues); proton pump inhibitors (omeprazole, lansoprazole); antidepressants (amitriptyline); antifungal agents (voriconazole); psychotropic drugs (diazepam), etc.
Alternative designation of the genetic marker is CYP2C19*3.
Period of execution
Within 7 days. The specified time does not include the day of biomaterial collection
Biomaterial type
- Buccal (cheek) epithelium
- Venous blood